LEO Pharma Acquires Dersimelagon for Up to $435 Million

Companies: LEO Pharma & Tanabe Pharma · Event Type: Global License Acquisition · Deal Value: Up to $435 Million (Upfront + Near-Term Milestones) · Product: Dersimelagon (MT-7117) · Indication: Erythropoietic & X-Linked Protoporphyria · Announcement Date: August 18, 2026 Summary LEO Pharma agreed to acquire…